Noema Pharma is a Swiss-based therapeutics company developing disease-transforming therapies to address the most disabling symptoms in neurological mediated conditions.

Noema’s research and development focuses on understanding and meeting patient needs using novel therapies. It leverages partnerships with patient communities, their families and caregivers, and partners with health care providers and policy makers. The business has a track record of successfully developing therapies for conditions affecting the nervous system. Noema strives to make a significant impact on overall well-being and neurological functioning of patients with persistent seizures in Tuberous Sclerosis Complex, severe pain in Trigeminal Neuralgia, involuntary tics associated with Tourette Syndrome and in women suffering from vasomotor symptoms during menopause.

In 2022, Gilde Healthcare was the largest investor in Noema’s CHF 54m (€51m) Series A financing round. A further investment was made in 2023 helping the firm raise CHF 103m (€105m) for its Series B round, which was used to advance its clinical-stage assets.